Latest news with #FrontiersinPharmacology
Yahoo
2 days ago
- Health
- Yahoo
Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration
Results demonstrate that intravenously administered therapeutic IgG antibodies can be detected in urine, supporting the conclusion that these antibodies are capable of crossing the kidney endothelial barrier This proof-of-concept study provides compelling support for the selected dosing regimen of MTx's investigational BK polyomavirus-neutralizing antibody Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or 'MTx'), a late-stage biotechnology company developing antibody-based therapies for viral infections and cancer, has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development. The study reports that, 0.015% (median) of the serum concentration of therapeutic antibody rituximab is found in the urine, with levels reaching up to 4.2%. These findings suggest that therapeutic IgG antibodies can cross the kidney filtration barrier in measurable amounts, challenging prior assumptions about size-exclusion limitations and supporting the feasibility of antibody-based interventions for renal infections. Christoph Esslinger, CSO of MTx, commented: 'This data reinforces the notion that potravitug can access infected renal tissue and supports the continued development of this first-in-class candidate for the treatment of BK viremia in kidney transplant recipients.' BKV nephropathy affects up to 70% of kidney transplant recipients with established BK viremia and is associated with compromised graft function and reduced long-term graft survival. Despite this, therapeutic options remain limited, partly due to the prevailing belief that large-molecule biologics cannot effectively penetrate kidney tissue. This study contributes to a growing body of evidence suggesting otherwise. MTx is currently conducting a Phase II double-blind, randomized, placebo-controlled trial with 90 patients in the USA for the treatment of BK viremia in kidney transplant recipients, with top line results anticipated later in 2025. The full publication can be accessed here. -Ends- Contacts Memo Therapeutics AG info@ ICR Healthcare Amber Fennell, Ashley Tapp memotx@ +44 (0)20 3709 5700 About Memo Therapeutics AGMemo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, is in Phase II development targeting BK viremia in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become a first-in-class BKV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn. Alongside potravitug, MTx is focused on discovering novel oncology targets. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at and on in to access your portfolio
Yahoo
2 days ago
- Health
- Yahoo
Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration
Results demonstrate that intravenously administered therapeutic IgG antibodies can be detected in urine, supporting the conclusion that these antibodies are capable of crossing the kidney endothelial barrier This proof-of-concept study provides compelling support for the selected dosing regimen of MTx's investigational BK polyomavirus-neutralizing antibody Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or 'MTx'), a late-stage biotechnology company developing antibody-based therapies for viral infections and cancer, has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development. The study reports that, 0.015% (median) of the serum concentration of therapeutic antibody rituximab is found in the urine, with levels reaching up to 4.2%. These findings suggest that therapeutic IgG antibodies can cross the kidney filtration barrier in measurable amounts, challenging prior assumptions about size-exclusion limitations and supporting the feasibility of antibody-based interventions for renal infections. Christoph Esslinger, CSO of MTx, commented: 'This data reinforces the notion that potravitug can access infected renal tissue and supports the continued development of this first-in-class candidate for the treatment of BK viremia in kidney transplant recipients.' BKV nephropathy affects up to 70% of kidney transplant recipients with established BK viremia and is associated with compromised graft function and reduced long-term graft survival. Despite this, therapeutic options remain limited, partly due to the prevailing belief that large-molecule biologics cannot effectively penetrate kidney tissue. This study contributes to a growing body of evidence suggesting otherwise. MTx is currently conducting a Phase II double-blind, randomized, placebo-controlled trial with 90 patients in the USA for the treatment of BK viremia in kidney transplant recipients, with top line results anticipated later in 2025. The full publication can be accessed here. -Ends- Contacts Memo Therapeutics AG info@ ICR Healthcare Amber Fennell, Ashley Tapp memotx@ +44 (0)20 3709 5700 About Memo Therapeutics AGMemo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, is in Phase II development targeting BK viremia in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become a first-in-class BKV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn. Alongside potravitug, MTx is focused on discovering novel oncology targets. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at and on in to access your portfolio
Associated Press
2 days ago
- Health
- Associated Press
Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration
Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or 'MTx'), a late-stage biotechnology company developing antibody-based therapies for viral infections and cancer, has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development. The study reports that, 0.015% (median) of the serum concentration of therapeutic antibody rituximab is found in the urine, with levels reaching up to 4.2%. These findings suggest that therapeutic IgG antibodies can cross the kidney filtration barrier in measurable amounts, challenging prior assumptions about size-exclusion limitations and supporting the feasibility of antibody-based interventions for renal infections. Christoph Esslinger, CSO of MTx, commented: 'This data reinforces the notion that potravitug can access infected renal tissue and supports the continued development of this first-in-class candidate for the treatment of BK viremia in kidney transplant recipients.' BKV nephropathy affects up to 70% of kidney transplant recipients with established BK viremia and is associated with compromised graft function and reduced long-term graft survival. Despite this, therapeutic options remain limited, partly due to the prevailing belief that large-molecule biologics cannot effectively penetrate kidney tissue. This study contributes to a growing body of evidence suggesting otherwise. MTx is currently conducting a Phase II double-blind, randomized, placebo-controlled trial with 90 patients in the USA for the treatment of BK viremia in kidney transplant recipients, with top line results anticipated later in 2025. The full publication can be accessed here. -Ends- About Memo Therapeutics AG Memo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, is in Phase II development targeting BK viremia in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become a first-in-class BKV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn. Alongside potravitug, MTx is focused on discovering novel oncology targets. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at and on LinkedIn.
Fox News
30-04-2025
- Health
- Fox News
Honey and allergy relief: Do these two really go together?
Spring is in the air – and so are seasonal allergies. "Spring can feel like a breath of fresh air, unless you're one of the millions dealing with seasonal allergies," said Dr. Joseph Mercola, a board-certified family physician based in Ormond Beach, Florida. "While trees bloom and flowers bud, you're left battling itchy eyes, sneezing fits or sinus pressure. If that sounds familiar, you're not alone." As many allergy sufferers seek help from alternative remedies, some scientific studies indicate that honey may indeed help relieve some of the pesky discomforts of seasonal allergies – although the research is far from definitive. Honey has health benefits because of its unique chemical composition, C. Marina Marchese told Fox News Digital. "It's a botanical fingerprint of a particular time and place, with potential wellness benefits that go far beyond the kitchen," said Marchese, founder of the American Honey Tasting Society in Weston, Connecticut. Honey might help with seasonal allergies, but the evidence is mixed. "Critics point out that the pollen found in honey mostly comes from flowers, while the kind that triggers your allergies is usually airborne from trees, grasses or weeds," Mercola told Fox News Digital. "Bees don't typically gather that kind in large amounts." A 2002 study by researchers at the University of Connecticut found no significant symptom relief in people with allergic rhino conjunctivitis after taking local or clover honey daily for 30 weeks. However, Mercola cited other studies that suggest honey does have anti-allergic potential. "In a 2021 mini-review published in Frontiers in Pharmacology, researchers examined both animal and human studies. In mice and rat models, honey reduced common allergy symptoms like sneezing, nasal rubbing and airway inflammation — pointing to a possible protective effect in controlled settings," he said. "In human trials, including one involving patients with allergic rhinitis, those who consumed Tualang honey saw a steady improvement in nasal congestion and sneezing, even after they stopped using antihistamines." The type of honey you consume matters, according to Mercola. "Clinical and preclinical research suggests that honeys like Tualang and Manuka may offer more potent anti-allergy effects," he said. "These varieties are rich in bioactive compounds like gallic acid, caffeic acid and kaempferol, which have been shown to dampen inflammatory pathways and reduce histamine release." Marchese also stresses the importance of avoiding commercial honey, pasteurized or ultra-filtered honey, which "lacks the pollens, enzymes and other beneficial compounds that might be helpful." Many honeys sold commercially in supermarkets are not the best quality of honey, Marchese told Fox News Digital, and are imported from various countries and blended, treated with heat at high temperatures and compromising the integrity of the honey. If honey is going to offer any potential benefit for allergies, Marchese said, it should be fresh, preferably from a backyard beekeeper, unheated and unfiltered. Even if honey doesn't eliminate your allergies completely, it offers other wellness benefits, Marchese said. "It's rich in antioxidants, has antibacterial properties and can help soothe sore throats and coughs," she said.
Gulf Insider
26-03-2025
- Health
- Gulf Insider
A New Study Says Baldness May Be Reversible
Researchers believe that sugar naturally occurring in the human body can help stimulate hair growth. Hair regrowth came after the formation of new blood vessels, thanks to a boost in the blood supply to hair follicles. Male pattern baldness impacts up to 50 percent of men worldwide with few FDA-licensed treatments. We've all been told that a spoonful of sugar helps the medicine go down, but research shows that a it may also help regrow hair. It gets a bit more scientific than that, but a recent study showed there's some promise in using a naturally occurring sugar found in the human body to stimulate blood flow to form new blood vessels and encourage hair regrowth. Testing the method worked in mice, and we all know the best laid schemes of mice and men may coexist, especially in a world where up to 50 percent of all men encounter male pattern baldness. In a 2024 study published in the journal Frontiers in Pharmacology , researchers at the University of Sheffield and COMSATS University Pakistan found that the natural sugar 2-deoxy-D-ribose (2dDR) can stimulate hair regrowth. 'Our research suggests that the answer to treating hair loss might be as simple as using a naturally occurring deoxy ribose sugar to boost the blood supply to the hair follicles to encourage hair growth,' Sheila MacNeil, emeritus professor of tissue engineering at the University of Sheffield, said in a statement. 'The research we have done is very much early stage, but the results are promising and warrant further investigation.' With only two drugs licensed by the FDA to treat male pattern baldness, a naturally occurring condition brought on by genetics, aging, stress, and hormones, MacNeil believes that the researchers are on track for something altogether new. As researchers spent eight years studying how the sugar can help to heal wounds on mice by promoting the formation of new blood vessels, they saw that the hair around those healing wounds appeared to grow more quickly compared to those that hadn't been treated. In came more mice. To study the hair regrowth side of the blood vessel research, the scientists created a model of testosterone-driven hair loss in mice to mimic human-style male pattern baldness and found that applying a small dose of the naturally occurring sugar helped to form new blood vessels. New blood vessels directly led to hair regrowth within weeks. The mice 'demonstrated an increase in length, diameter, hair follicle density, anagen/telogen ratio, diameter of hair follicles, area of the hair bulb covered in melanin, and an increase in the number of blood vessels,' the authors wrote. 'This pro-angiogenic deoxy ribose sugar is naturally occurring, inexpensive, and stable, and we have shown it can be delivered from a variety of carrier gels or dressings,' Muhammed Yar, associate professor at COMSATS University Pakistan, said in a statement. 'This makes it an attractive candidate to explore further for treatment of hair loss in men.' Of the two drugs licensed to treat hair loss, minoxidil (brand name Rogaine) is topical and approved for men and women, and finasteride (brand name Propecia) is taken orally, has been linked to side effects, and is not considered suitable for women. The study claims the deoxy ribose sugar proved as successful as minoxidil at regrowing hair, with both between 80 and 90 percent effective. That's a lot of new blood vessels, and a fair bit of new hair. 'This could offer another approach,' MacNeil said, 'to treating this condition.' Also read: Court Orders Father To Pay Legal Fees For Refusing To Apply For Child's Passport
